Guggenheim analyst Michael Schmidt raised the firm’s price target on Tango Therapeutics (TNGX) to $12 from $10 and keeps a Buy rating on the shares after the company disclosed Phase 1/2 vopimetostat data in solid tumor patients. The firm is updating its model and estimates and increasing its odds of success assumption for vopimetostat following the data.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX: